PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis

Cell Death and Differentiation

Volumn 21, Issue 9, 2014, Pages 1469-1481

  Paul, A ^a,b   Gunewardena, S ^c   Stecklein, S R ^a,b   Saha, B ^b   Parelkar, N ^a   Danley, M ^a,b   Rajendran, G ^b   Home, P ^b   Ray, S ^b   Jokar, I ^a   Vielhauer, G A ^b   Jensen, R A ^a,b   Tawfik, O ^a,b   Paul, S ^a,b  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; PROTEIN KINASE C; PROTEIN KINASE C LAMBDA; PROTEIN KINASE C ZETA;

ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; FEMALE; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PATHOLOGY; SCID MOUSE; SECONDARY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84905922713     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.62     Document Type: Article

References (60)

1. Stecklein SR, Jensen RA, Pal A. Genetic and epigenetic signatures of breast cancer subtypes. Front BiosciElite Ed, 2012; 4: 934-949.
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
3. Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012; 2012: 217185.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al. Triplenegative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15 Pt 1): 4429-4434.
5. Yagata H, Kajiura Y, Yamauchi H. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer 2011; 18: 165-173.
6. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009; 115: 423-428.
7. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
8. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009; 20: 1913-1927.
9. Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat 2009; 118: 131-137.
10. Fields AP, Regala RP. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res 2007; 55: 487-497.
11. Urtreger AJ, Kazanietz MG. Bal de Kier Joffe ED. Contribution of individual PKC isoforms to breast cancer progression. IUBMB Life 2012; 64: 18-26.
12. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7: 281-294.
13. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett 2006; 235: 1-10.
14. McCaffrey LM, Montalbano J, Mihai C, Macara IG. Loss of the par3 polarity protein promotes breast tumorigenesis and metastasis. Cancer Cell 2012; 22: 601-614.
15. Suzuki A, Akimoto K, Ohno S. Protein kinase C lambda/iota (PKClambda/iota): a PKC isotype essential for the development of multicellular organisms. J Biochem 2003; 133: 9-16.
16. Suzuki S, Moore DH 2nd, Ginzinger DG, Godfrey TE, Barclay J, Powell B et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 2000; 60: 5382-5385.
17. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 12519-12524.
18. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, Lohse CM et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 2005; 65: 8905-8911.
19. Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 2005; 280: 31109-31115.
20. Scotti ML, Bamlet WR, Smyrk TC, Fields AP, Murray NR. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res 2010; 70: 2064-2074.
21. Takagawa R, Akimoto K, Ichikawa Y, Akiyama H, Kojima Y, Ishiguro H et al. High expression of atypical protein kinase C lambda/iota in gastric cancer as a prognostic factor for recurrence. Ann Surg Oncol 2010; 17: 81-88.
22. Murray NR, Jamieson L, Yu W, Zhang J, Gokmen-Polar Y, Sier D et al. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 2004; 164: 797-802.
23. Yang YL, Chu JY, Luo ML, Wu YP, Zhang Y, Feng YB et al. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 2008; 47: 127-136.
24. Du GS, Wang JM, Lu JX, Li Q, Ma CQ, Du JT et al. Expression of P-aPKC-iota, E-cadherin, and beta-catenin related to invasion and metastasis in hepatocellular carcinoma. Ann Surg Oncol 2009; 16: 1578-1586.
25. Li Q, Wang JM, Liu C, Xiao BL, Lu JX, Zou SQ. Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2008; 7: 70-75.
26. Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, Ishiguro-Imagawa Y et al. aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci USA 2009; 106: 16369-16374.
27. Patel R, Win H, Desai S, Patel K, Matthews JA, Acevedo-Duncan M. Involvement of PKC-iota in glioma proliferation. Cell Prolif 2008; 41: 122-135.
28. Kojima Y, Akimoto K, Nagashima Y, Ishiguro H, Shirai S, Chishima T et al. The overexpression and altered localization of the atypical protein kinase C lambda/iota in breast cancer correlates with the pathologic type of these tumors. Hum Pathol 2008; 39: 824-831.
29. Paget JA, Restall IJ, Daneshmand M, Mersereau JA, Simard MA, Parolin DA et al. Repression of cancer cell senescence by PKCiota. Oncogene 2012; 31: 3584-3596.
30. Izumi Y, Hirose T, Tamai Y, Hirai S, Nagashima Y, Fujimoto T et al. An atypical PKC directly associates and colocalizes at the epithelial tight junction with ASIP, a mammalian homologue of Caenorhabditis elegans polarity protein PAR-3. J Cell Biol 1998; 143: 95-106.
31. Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP et al. Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol 2006; 8: 1235-1245.
32. Joberty G, Petersen C, Gao L, Macara IG. The cell-polarity protein Par6 links Par3 and atypical protein kinase C to Cdc42. Nat Cell Biol 2000; 2: 531-539.
33. Ishiuchi T, Takeichi M. Willin and Par3 cooperatively regulate epithelial apical constriction through aPKC-mediated ROCK phosphorylation. Nat Cell Biol 2011; 13: 860-866.
34. Wald FA, Forteza R, Diwadkar-Watkins R, Mashukova A, Duncan R, Abreu MT et al. Aberrant expression of the polarity complex atypical PKC and non-muscle myosin IIA in active and inactive inflammatory bowel disease. Virchows Arch 2011; 459: 331-338.
35. Kikuchi K, Soundararajan A, Zarzabal LA, Weems CR, Nelon LD, Hampton ST et al. Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2013; 32: 286-295.
36. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009; 137: 635-646.
37. Messerschmidt A, Macieira S, Velarde M, Badeker M, Benda C, Jestel A et al. Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. J Mol Biol 2005; 352: 918-931.
38. Wald FA, Oriolo AS, Mashukova A, Fregien NL, Langshaw AH, Salas PJ. Atypical protein kinase C (iota) activates ezrin in the apical domain of intestinal epithelial cells. J Cell Sci 2008; 121(Pt 5): 644-654.
39. Avila MA, Velasco JA, Cansado J, Notario V. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res 1994; 54: 2424-2428.
40. Castles CG, Fuqua SA, Klotz DM, Hill SM. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 1993; 53: 5934-5939.
41. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998; 58: 3237-3242.
42. Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol 2010; 4: 357-368.
43. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006; 66: 5278-5286.
44. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005; 7: R953-R964.
45. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679.
46. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013; 15: 807-817.
47. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520.
48. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T et al. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011; 11: 130.
49. Dutta D, Ray S, Home P, Larson M, Wolfe MW, Paul S. Self-renewal versus lineage commitment of embryonic stem cells: protein kinase C signaling shifts the balance. Stem Cells 2011; 29: 618-628.
50. Duran A, Diaz-Meco MT, Moscat J. Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J 2003; 22: 3910-3918.
51. Lee KY, Ito K, Hayashi R, Jazrawi EP, Barnes PJ, Adcock IM. NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription. J Immunol 2006; 176: 603-615.
52. Martone R, Euskirchen G, Bertone P, Hartman S, Royce TE, Luscombe NM et al. Distribution of NF-kappaB-binding sites across human chromosome 22. Proc Natl Acad Sci USA 2003; 100: 12247-12252.
53. Anrather J, Racchumi G, Iadecola C. cis-acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B. J. Biol Chem 2005; 280: 244-252.
54. Wang W, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999; 18: 4554-4563.
55. Chen LF, Williams SA, Mu Y, Nakano H, Duerr JM, Buckbinder L et al. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 2005; 25: 7966-7975.
56. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
57. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008; 133: 66-77.
58. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8: 1369-1375.
59. Szabo A, Perou CM, Karaca M, Perreard L, Palais R, Quackenbush JF et al. Statistical modeling for selecting housekeeper genes. Genome Biol 2004; 5: R59.
60. Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 2012; 18: 529-537.